Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | STK17B | O94768 | 2/20 | 0.34 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.34 |
| ▸ | CAMKK1 | Q8N5S9 | 1/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.34 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.34 |
| ▸ | NPY2R | P49146 | 1/20 | 0.34 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.33 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.33 |
| ▸ | RPA1 | P27694 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17438680 | 0.76 | S100A4 (0.38) | NPC1RAB9ASMN1; SMN2HSD17B2S100A4 | |
| SCHEMBL17438712 | 0.76 | RAB9A (0.47) | NPC1RAB9ASMN1; SMN2S100A4 | |
| SCHEMBL3787647 | 0.75 | MAOA (0.33) | NPC1RAB9ASMN1; SMN2NQO1NQO2 | |
| SCHEMBL1247110 | 0.74 | TDP1 (0.40) | NPC1RAB9ASMN1; SMN2CYP3A4S100A4 | |
| SCHEMBL324177 | 0.72 | MAOB (0.44) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29710475 | 0.71 | APP (0.54) | APPNPC1RAB9ASMN1; SMN2CYP3A4 | |
| SCHEMBL6981693 | 0.71 | LMNA (0.39) | NPC1RAB9ASMN1; SMN2CYP3A4 | |
| SCHEMBL1724293 | 0.70 | ELANE (0.35) | NPC1RAB9ASMN1; SMN2CYP3A4S100A4 | |
| SCHEMBL15952376 | 0.70 | ALDH1A1 (0.33) | CYP3A4 | |
| SCHEMBL19133572 | 0.70 | APP (0.57) | APPCYP19A1HSD17B1HSD17B2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 475 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216380-A1 | BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment | ACERTA PHARMA BV (NL) | 2024-07-04 | — | — | US | disclosed |
| US-20240197738-A1 | COMPOUND 7AI IN TREATING EWING SARCOMA BY INHIBITING OTUD7A | Atomwise Inc. | 2024-06-20 | — | — | US | disclosed |
| US-20240197742-A1 | Therapeutic Combinations of a CD19 Inhibitor and a BTK Inhibitor | ACERTA PHARMA BV (NL) | 2024-06-20 | — | — | US | disclosed |
| US-20240180904-A1 | Methods of Treating Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia Using a BTK Inhibitor | ACERTA PHARMA BV (NL) | 2024-06-06 | — | — | US | disclosed |
| WO-2024119099-A1 | GALLIUM-SALOPHEN ANTIMICROBIAL COMPOUNDS AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2024-06-06 | — | — | WO | disclosed |
| US-20240174630-A1 | SELECTIVE HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF HUMAN DISEASE | SHUTTLE PARMACEUTICALS, LLC | 2024-05-30 | — | — | US | disclosed |
| EP-4370109-A1 | SUBEROYLANILIDE HYDROXAMIC ACID (SAHA) DRUGS, CONJUGATES, AND NANOPARTICLES, AND METHODS OF USE THEREOF | University of Maryland, Baltimore (US) | 2024-05-22 | — | — | EP | disclosed |
| WO-2024097204-A1 | GRAFTABLE BIOCIDAL LINKERS AND POLYMERS AND USES THEREOF | DEBOGY MOLECULAR, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20240150315-A1 | BETA-2 ADRENORECEPTOR MODULATORS AND METHODS OF USING SAME | THOMAS JEFFERSON UNIVERSITY | 2024-05-09 | — | — | US | disclosed |
| US-20240140940-A1 | CARBOXYLIC ACID, ACYL SULFONAMIDE AND ACYL SULFAMIDE-DERIVATIZED BICYCLIC AZA-HETEROAROMATICS AS SELECTIVE MCL-1 INHIBITORS AND AS DUAL MCL-1/BCL-2 INHIBITORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2024-05-02 | — | — | US | disclosed |
| US-7393869-B2 | Methods of using thiazolidine derivatives to treat cancer or inflammation | QLT INC. (CA) | 2008-07-01 | — | — | US | disclosed |
| US-20080153815-A1 | PINANE-SUBSTITUTED PYRIMIDINEDIAMINE DERIVATIVES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-06-26 | — | — | US | disclosed |
| US-7335658-B2 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2008-02-26 | — | — | US | disclosed |
| US-20070087363-A1 | Therapeutic methods, compounds and compositions | MYRIAD GENETICS, INCORPORATED (US) | 2007-04-19 | — | — | US | disclosed |
| US-20060252767-A1 | Piperazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-11-09 | — | — | US | disclosed |
| US-20060205713-A1 | Antidiabetic agents; disease of glucose tolerance; insulin resistance; obesity; dyslipidemia; metabolic disorders; liver disorders; [4-(6-Phenethyloxy-pyridazin-3-yl)piperazin-1-yl]-(2-trifluoromethyl-phenyl)-methanone; stearoyl-CoA desaturase modulators | XENON PHARMACEUTICALS INC. (CA) | 2006-09-14 | — | — | US | disclosed |
| US-20060183782-A1 | Methods of using thiazolidine derivatives to treat cancer or inflammation | QLT INC. (CA) | 2006-08-17 | — | — | US | disclosed |
| US-20050065143-A1 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2005-03-24 | — | — | US | disclosed |
| US-20040180921-A1 | Substituted imidazo[1,2-a]pyridine derivatives | MUTEL VINCENT (FR) | 2004-09-16 | — | — | US | disclosed |
| US-6355641-B1 | HYPOTENSIVE AGENTS AND WOUND HEALING AGENTS | SYNTEX (U.S.A.) LLC | 2002-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065143-A1 | Pyridazine derivatives and their use as therapeutic agents | PRDX5, SNRPD3, SNRPD2 | APP 2058/4885NPC1 797/4885RAB9A 44/4885 |
| US-20240150315-A1 | BETA-2 ADRENORECEPTOR MODULATORS AND METHODS OF USING SAME | ADRB2, ADRB1, ADRA2A | APP 912/4885NPC1 2494/4885RAB9A 3269/4885 |
| US-20240140940-A1 | CARBOXYLIC ACID, ACYL SULFONAMIDE AND ACYL SULFAMIDE-DERIVATIZED BICYCLIC AZA-HETEROAROMATICS AS SELECTIVE MCL-1 INHIBITORS AND AS DUAL MCL-1/BCL-2 INHIBITORS | MCL1, BCLAF1, BCL2A1 | APP 4784/4885NPC1 3155/4885RAB9A 4106/4885 |
| US-20240216380-A1 | BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment | BTK, LYN, SYK | APP 4017/4885NPC1 3117/4885RAB9A 1801/4885 |
| US-20240180904-A1 | Methods of Treating Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia Using a BTK Inhibitor | BTK, LYN, SYK | APP 4553/4885NPC1 4239/4885RAB9A 2800/4885 |
| US-20060183782-A1 | Methods of using thiazolidine derivatives to treat cancer or inflammation | PTPN2, PTPRCAP, PTPN5 | APP 4602/4885NPC1 2614/4885RAB9A 4072/4885 |
| US-20240174630-A1 | SELECTIVE HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF HUMAN DISEASE | HDAC1, HDAC2, HDAC5 | APP 3182/4885NPC1 1920/4885RAB9A 3285/4885 |
| US-20040180921-A1 | Substituted imidazo[1,2-a]pyridine derivatives | GRM5, GRM1, GRIK5 | APP 3695/4885NPC1 413/4885RAB9A 982/4885 |
| US-20240197742-A1 | Therapeutic Combinations of a CD19 Inhibitor and a BTK Inhibitor | BTK, CD274, BCL9 | APP 2721/4885NPC1 3240/4885RAB9A 1056/4885 |
| US-20060252767-A1 | Piperazine derivatives and their use as therapeutic agents | ARG2, S1PR5, S1PR1 | APP 2109/4885NPC1 127/4885RAB9A 53/4885 |
| US-20070087363-A1 | Therapeutic methods, compounds and compositions | APP, BACE1, PSEN1 | APP 1/4885NPC1 31/4885RAB9A 1976/4885 |
| US-20080153815-A1 | PINANE-SUBSTITUTED PYRIMIDINEDIAMINE DERIVATIVES USEFUL AS AXL INHIBITORS | AXL, TYRO3, MERTK | APP 1776/4885NPC1 3839/4885RAB9A 2279/4885 |
| US-20060205713-A1 | Antidiabetic agents; disease of glucose tolerance; insulin resistance; obesity; dyslipidemia; metabolic disorders; liver disorders; [4-(6-Phenethyloxy-pyridazin-3-yl)piperazin-1-yl]-(2-trifluoromethyl-phenyl)-methanone; stearoyl-CoA desaturase modulators | GPR119, SCD, CPT1A | APP 3676/4885NPC1 239/4885RAB9A 597/4885 |
| US-20240197738-A1 | COMPOUND 7AI IN TREATING EWING SARCOMA BY INHIBITING OTUD7A | OTUD7B, USP7, UBQLN1 | APP 3340/4885NPC1 3984/4885RAB9A 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.